Drug intelligence / Profile preview

PK091

Development stage: Preclinical
Lead developer: PharmaKure
Modality: Small Molecules
Administration: Oral

Overview

PK091 is a preclinical-stage drug candidate being developed by PharmaKure for the treatment of Gerstmann-Sträussler-Scheinker syndrome (GSS). GSS is a rare, fatal, and typically inherited neurodegenerative prion disease characterized by the accumulation of abnormal prion protein (PrP) aggregates in the brain. PharmaKure's development strategy involves utilizing a proprietary platform to identify and repurpose existing drugs that can interfere with the formation or stability of toxic protein aggregates. PK091 is designed to target the underlying protein misfolding pathology associated with GSS, aiming to slow or halt disease progression.

Targets

Aβ (Amyloid-beta peptides and aggregates)TauO (Microtubule-associated protein tau oligomer)PrPSc (Major prion protein)

Beyond the preview

Go deeper on PK091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PK091.

Explore the full profile